This study looks at how safe and effective two new drugs, tuvusertib and niraparib or lartesertib, are for treating epithelial ovarian cancer. Participants should have a type of cancer called high-grade serous or endometrioid cancer that has come back after treatment. The study wants to see if these drugs can help tumors shrink or disappear. To join, participants must have a mutation in certain genes (BRCA1 or BRCA2) or a positive HRD status, which means their cancer cells have trouble fixing themselves. They must also have tried a treatment called PARP inhibitor before, but it didn't work.

• The study will last as long as the doctors see any benefits or side effects.
• Participants must visit the study center regularly for check-ups and treatments.
• There might be risks like side effects from the drugs, which doctors will monitor closely.

Participants should not join if they have other serious illnesses, certain cancer histories, or active infections. The study aims to improve treatment options for ovarian cancer, but participants should discuss the potential risks and benefits with their doctor before deciding to join.